2.78
-0.39(-12.30%)
Currency In USD
| Previous Close | 3.17 |
| Open | 2.86 |
| Day High | 2.86 |
| Day Low | 2.76 |
| 52-Week High | 15.7 |
| 52-Week Low | 1.72 |
| Volume | 181,338 |
| Average Volume | 3.29M |
| Market Cap | 3.36M |
| PE | -0.24 |
| EPS | -11.65 |
| Moving Average 50 Days | 2.86 |
| Moving Average 200 Days | 3.65 |
| Change | -0.39 |
If you invested $1000 in InMed Pharmaceuticals Inc. (INM) 10 years ago, it would be worth $1.13 as of July 16, 2025 at a share price of $2.78. Whereas If you bought $1000 worth of InMed Pharmaceuticals Inc. (INM) shares 5 years ago, it would be worth $1.04 as of July 16, 2025 at a share price of $2.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
Newsfile
Jun 27, 2025 11:00 AM GMT
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Newsfile
Jun 25, 2025 12:00 PM GMT
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Newsfile
Jun 24, 2025 11:00 AM GMT
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegenerationReduces key pro-inflammatory mark